1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9732053
SERIAL NO

14902326

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions for oral administration comprising an effective amount of the crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate. Moreover, the present invention relates to the use of crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate for the preparation of pharmaceutical compositions.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • LEK PHARMACEUTICALS D.D.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Adamer, Verena Innsbruck, AT 10 5
Hotter, Andreas Kundl, AT 25 116
Pichler, Arthur Kundl, AT 23 75
Ziegert-Knepper, Robert Kundl, AT 1 1

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 15, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 15, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00